Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Colorectal Cancer · Esophageal Varices in NASH Cirrhosis · GALT

Galectin Therapeutics

GALECTIN THERAPEUTICS INC

Galectin Therapeutics patent portfolio — 20 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071, US HQ
2000 Founded
36 Employees
Public company Type
GALT · NYSE Ticker
Company details
Status
Public
HQ
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071, US
Founded
2000
Employees
36
Programs
12
Drugs
5
Patents
20
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Galectin Therapeutics patents

20 pharmaceutical patents indexed for Galectin Therapeutics. 0 expire within 24 months.

Galectin Therapeutics has 20 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

20 patents

Patent portfolio

  1. US 12377102

    Compounds for the prevention and treatment of medical disorders and uses thereof

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11583530

    Compounds for the prevention and treatment of medical disorders and uses thereof

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11576924

    Compounds for the prevention and treatment of diseases and the use thereof

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11413303

    Methods for treatment of arthritis

    Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10799525

    Composition of novel carbohydrate drug for treatment of human diseases

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10744154

    Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10420793

    Composition of novel carbohydrate drug for treatment of human diseases

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9974802

    Composition of novel carbohydrate drug for treatment of human diseases

    Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9968631

    Method for treatment of pulmonary fibrosis

    Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9763974

    Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9649327

    Composition of novel carbohydrate drug for treatment of human diseases

    Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9339515

    Method for treatment of pulmonary fibrosis

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9200090

    Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8962824

    Composition of novel carbohydrate drug for treatment of human diseases

    Expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8871925

    Compositions of novel carbohydrate drug for treatment of human diseases

    Expires Mon Oct 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8828971

    Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders

    Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8722645

    Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

    Expires Mon May 08 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8658787

    Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease

    Expires Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8367638

    Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

    Expires Mon Jan 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8236780

    Galactose—pronged polysaccharides in a formulation for antifibrotic therapies

    Expires Mon Aug 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Galectin Therapeutics have?

20 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Galectin Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.